+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
New

Metabolic Dysfunction-Associated Steatohepatitis Market Outlook 2026-2034

  • PDF Icon

    Report

  • 160 Pages
  • November 2026
  • Region: Global
  • OG Analysis
  • ID: 6291219
The Metabolic Dysfunction-Associated Steatohepatitis (MASH/NASH) Market is estimated at USD 2.6 billion in 2026 and is projected to reach USD 16.7 billion by 2034, growing at a CAGR of 26.2% during 2026-2034.

Market Overview

MASH, formerly termed NASH, coverage distinguishes specifically authorized medicines, diagnostic assessment and separately identified development programs. Appropriate diagnosis and treatment access shape demand in MASH, formerly termed NASH. Authorized medicines, diagnostics and investigational programs occupy different commercial stages.

Eligibility assessment and variable access complicate treatment uptake. Defined referral pathways and product-specific evidence support market development. Approvals, coverage and diagnostic capacity differ between countries. Product positioning depends on appropriate clinical evidence, local authorization and formulation availability, with access conditions differing between healthcare systems. Procurement and prescribing involve different stakeholders. Manufacturers, distributors, clinicians and payers influence availability without performing interchangeable roles in the value chain. Supply decisions require documented quality and dependable distribution. Manufacturing capability, product-specific authorization and finished-dose availability represent distinct qualification considerations. Payer and pharmacy requirements shape practical purchasing. Packaging, replenishment and supply continuity can influence procurement alongside the pharmaceutical product itself.

Key Takeaways

  • Demand drivers: Appropriate diagnosis and treatment access shape demand in MASH, formerly termed NASH. Disease prevalence alone does not establish the revenue available to any particular medicine or supplier. Commercial demand reflects the number of eligible treated patients, continuity of access and the medicines selected within established care pathways.
  • Technology and performance: Authorized medicines, diagnostics and investigational programs occupy different commercial stages. Products within the same therapeutic area should not be treated as clinically interchangeable. Purchasing analysis separates originator and alternative products, where available, and considers how national access arrangements influence realized demand.
  • Challenges and economics: Eligibility assessment and variable access complicate treatment uptake. Coverage, dispensing channels and reliable supply also influence whether appropriate treatment reaches eligible patients over time. Product development is evaluated separately from medicines already available through authorized channels.
  • Commercial opportunities: Defined referral pathways and product-specific evidence support market development. Commercial opportunity depends on evidence and permitted uses. Formulation development and access initiatives require evaluation within the relevant national treatment and purchasing environment.
  • Geographic considerations: Approvals, coverage and diagnostic capacity differ between countries. Reimbursement, prescribing and distribution conditions can differ substantially between countries. International availability cannot be inferred solely from a product being marketed elsewhere.
  • Application requirements: MASH, formerly termed NASH, coverage distinguishes specifically authorized medicines, diagnostic assessment and separately identified development programs. Procurement and prescribing involve different stakeholders. Manufacturers, distributors, clinicians and payers influence availability without performing interchangeable roles in the value chain.
  • Quality and qualification: Supply decisions require documented quality and dependable distribution. Manufacturing capability, product-specific authorization and finished-dose availability represent distinct qualification considerations. Authorized medicines, diagnostics and investigational programs occupy different commercial stages.
  • Purchasing and delivery: Buyers distinguish authorized indications, pipeline assets and broader metabolic-care products. Payer and pharmacy requirements shape practical purchasing. Packaging, replenishment and supply continuity can influence procurement alongside the pharmaceutical product itself.
  • Competitive positioning: Madrigal Pharmaceuticals, Novo Nordisk and Roche are among the companies covered. The analysis distinguishes relevant product, technology and channel roles, with emphasis on application fit, supply capabilities and customer support.
  • Outlook priorities: The metabolic dysfunction-associated steatohepatitis (mash/nash) outlook depends on the interaction of end-use demand, product qualification and commercially viable delivery. Defined referral pathways and product-specific evidence support market development. Approvals, coverage and diagnostic capacity differ between countries.

Competitive Landscape

Competition separates authorized MASH products from investigational programs and adjacent metabolic portfolios. Madrigal and Novo Nordisk provide established authorized-treatment references, while the other named businesses occupy different development positions. Novo Nordisk includes Akero and Roche includes 89bio rather than counting acquired businesses as independent competitors. Comparison depends on actual indications, eligibility, clinical evidence and access. Pipeline inclusion does not establish future approval or revenue. Broader obesity or diabetes sales are not wholly assigned to MASH. The report assesses product-level positioning and development risk rather than presenting all corporate portfolios as directly interchangeable treatments.

Companies Mentioned

  • Madrigal Pharmaceuticals
  • Novo Nordisk
  • Roche
  • Eli Lilly
  • Viking Therapeutics
  • Inventiva
  • Boehringer Ingelheim
  • Gilead Sciences
  • Galectin Therapeutics
  • Arrowhead Pharmaceuticals

Metabolic Dysfunction-Associated Steatohepatitis (MASH/NASH) Market Analytics

The report employs rigorous tools, including Porter’s Five Forces, value chain mapping, and scenario-based modelling, to assess supply-demand dynamics. Cross-sector influences from parent, derived, and substitute markets are evaluated to identify risks and opportunities. Trade and pricing analytics provide an up-to-date view of international flows, including leading exporters, importers, and regional price trends.

Macroeconomic indicators, policy frameworks such as carbon pricing and energy security strategies, and evolving consumer behaviour are considered in forecasting scenarios. Recent deal flows, partnerships, and technology innovations are incorporated to assess their impact on future market performance.

Metabolic Dysfunction-Associated Steatohepatitis (MASH/NASH) Market Competitive Intelligence

The competitive landscape is mapped through proprietary frameworks, profiling leading companies with details on business models, product portfolios, financial performance, and strategic initiatives. Key developments such as mergers & acquisitions, technology collaborations, investment inflows, and regional expansions are analysed for their competitive impact. The report also identifies emerging players and innovative startups contributing to market disruption.

Regional insights highlight the most promising investment destinations, regulatory landscapes, and evolving partnerships across the report’s covered markets.

Countries Covered

  • North America - Metabolic Dysfunction-Associated Steatohepatitis (MASH/NASH) Market data and outlook to 2034
    • United States
    • Canada
    • Mexico

  • Europe - Metabolic Dysfunction-Associated Steatohepatitis (MASH/NASH) Market data and outlook to 2034
    • Germany
    • United Kingdom
    • France
    • Italy
    • Spain
    • BeNeLux
    • Russia
    • Sweden

  • Asia-Pacific - Metabolic Dysfunction-Associated Steatohepatitis (MASH/NASH) Market data and outlook to 2034
    • China
    • Japan
    • India
    • South Korea
    • Australia
    • Indonesia
    • Malaysia
    • Vietnam

  • Middle East and Africa - Metabolic Dysfunction-Associated Steatohepatitis (MASH/NASH) Market data and outlook to 2034
    • Saudi Arabia
    • South Africa
    • Iran
    • UAE
    • Egypt

  • South and Central America - Metabolic Dysfunction-Associated Steatohepatitis (MASH/NASH) Market data and outlook to 2034
    • Brazil
    • Argentina
    • Chile
    • Peru
* We can include data and analysis of additional countries on demand.

Research Methodology

This study combines primary inputs from industry experts across the Metabolic Dysfunction-Associated Steatohepatitis (MASH/NASH) value chain with secondary data from associations, government publications, trade databases, and company disclosures. Proprietary modeling techniques, including data triangulation, statistical correlation, and scenario planning, are applied to deliver reliable market sizing and forecasting.

Key Questions Addressed

  • What are the current market size and outlook across the covered markets?
  • Which product and customer categories offer the most relevant opportunities?
  • How do supply conditions, pricing and competitive strategies affect market development?
  • Which risks and practical investment considerations should decision makers evaluate?

Your Key Takeaways from the Metabolic Dysfunction-Associated Steatohepatitis (MASH/NASH) Market Report

  • Global Metabolic Dysfunction-Associated Steatohepatitis (MASH/NASH) Market size and growth projections (CAGR), 2026-2034
  • Impact of geopolitical developments on Metabolic Dysfunction-Associated Steatohepatitis (MASH/NASH) trade, costs, and supply chains
  • Metabolic Dysfunction-Associated Steatohepatitis (MASH/NASH) Market size, share, and outlook across the 5 regions and country/subregional markets listed above, 2026-2034
  • Metabolic Dysfunction-Associated Steatohepatitis (MASH/NASH) Market size, CAGR, and market share of key products, applications, and end-user verticals, 2026-2034
  • Short- and long-term Metabolic Dysfunction-Associated Steatohepatitis (MASH/NASH) Market trends, drivers, restraints, and opportunities
  • Porter’s Five Forces analysis, technological developments, and Metabolic Dysfunction-Associated Steatohepatitis (MASH/NASH) supply chain analysis
  • Metabolic Dysfunction-Associated Steatohepatitis (MASH/NASH) trade analysis, Metabolic Dysfunction-Associated Steatohepatitis (MASH/NASH) Market price analysis, and Metabolic Dysfunction-Associated Steatohepatitis (MASH/NASH) supply/demand dynamics
  • Company profiles covering business overview, key strategies, financial information where available, and relevant products
  • Latest Metabolic Dysfunction-Associated Steatohepatitis (MASH/NASH) Market news and developments

This product will be delivered within 1-3 business days.

Table of Contents

1. Table of Contents
1.1 List of Tables
1.2 List of Figures
2. Global Metabolic Dysfunction-Associated Steatohepatitis (MASH/NASH) Market Summary, 2026
2.1 Metabolic Dysfunction-Associated Steatohepatitis (MASH/NASH) Industry Overview
2.1.1 Global Metabolic Dysfunction-Associated Steatohepatitis (MASH/NASH) Market Revenues (In US$ billion)
2.2 Metabolic Dysfunction-Associated Steatohepatitis (MASH/NASH) Market Scope
2.3 Research Methodology
3. Metabolic Dysfunction-Associated Steatohepatitis (MASH/NASH) Market Insights, 2025-2035
3.1 Metabolic Dysfunction-Associated Steatohepatitis (MASH/NASH) Market Drivers
3.2 Metabolic Dysfunction-Associated Steatohepatitis (MASH/NASH) Market Restraints
3.3 Metabolic Dysfunction-Associated Steatohepatitis (MASH/NASH) Market Opportunities
3.4 Metabolic Dysfunction-Associated Steatohepatitis (MASH/NASH) Market Challenges
3.5 Tariff Impact on Global Metabolic Dysfunction-Associated Steatohepatitis (MASH/NASH) Supply Chain Patterns
4. Metabolic Dysfunction-Associated Steatohepatitis (MASH/NASH) Market Analytics
4.1 Metabolic Dysfunction-Associated Steatohepatitis (MASH/NASH) Market Size and Share, Key Product, 2026 Vs 2035
4.2 Metabolic Dysfunction-Associated Steatohepatitis (MASH/NASH) Market Size and Share, Dominant Application, 2026 Vs 2035
4.3 Metabolic Dysfunction-Associated Steatohepatitis (MASH/NASH) Market Size and Share, Leading Sales Channel, 2026 Vs 2035
4.4 Metabolic Dysfunction-Associated Steatohepatitis (MASH/NASH) Market Size and Share, High Growth Countries, 2026 Vs 2035
4.5 Five Forces Analysis for Global Metabolic Dysfunction-Associated Steatohepatitis (MASH/NASH) Market
4.5.1 Metabolic Dysfunction-Associated Steatohepatitis (MASH/NASH) Industry Attractiveness Index, 2026
4.5.2 Metabolic Dysfunction-Associated Steatohepatitis (MASH/NASH) Supplier Intelligence
4.5.3 Metabolic Dysfunction-Associated Steatohepatitis (MASH/NASH) Buyer Intelligence
4.5.4 Metabolic Dysfunction-Associated Steatohepatitis (MASH/NASH) Competition Intelligence
4.5.5 Metabolic Dysfunction-Associated Steatohepatitis (MASH/NASH) Product Alternatives and Substitutes Intelligence
4.5.6 Metabolic Dysfunction-Associated Steatohepatitis (MASH/NASH) Market Entry Intelligence
5. Global Metabolic Dysfunction-Associated Steatohepatitis (MASH/NASH) Market Statistics - Industry Revenue, Market Share, Growth Trends and Forecast by segments, to 2035
5.1 World Metabolic Dysfunction-Associated Steatohepatitis (MASH/NASH) Market Size, Potential and Growth Outlook, 2025-2035
5.1 Global Metabolic Dysfunction-Associated Steatohepatitis (MASH/NASH) Sales Outlook and CAGR Growth By Product, 2025-2035
5.2 Global Metabolic Dysfunction-Associated Steatohepatitis (MASH/NASH) Sales Outlook and CAGR Growth By Application, 2025-2035
5.3 Global Metabolic Dysfunction-Associated Steatohepatitis (MASH/NASH) Sales Outlook and CAGR Growth By Sales Channel, 2025-2035
5.4 Global Metabolic Dysfunction-Associated Steatohepatitis (MASH/NASH) Market Sales Outlook and Growth by Region, 2025-2035
6. Asia-Pacific Metabolic Dysfunction-Associated Steatohepatitis (MASH/NASH) Industry Statistics - Market Size, Share, Competition and Outlook
6.1 Asia-Pacific Metabolic Dysfunction-Associated Steatohepatitis (MASH/NASH) Market Insights, 2026
6.2 Asia-Pacific Metabolic Dysfunction-Associated Steatohepatitis (MASH/NASH) Market Revenue Forecast By Product, 2025-2035
6.3 Asia-Pacific Metabolic Dysfunction-Associated Steatohepatitis (MASH/NASH) Market Revenue Forecast By Application, 2025-2035
6.4 Asia-Pacific Metabolic Dysfunction-Associated Steatohepatitis (MASH/NASH) Market Revenue Forecast By Sales Channel, 2025-2035
6.5 Asia-Pacific Metabolic Dysfunction-Associated Steatohepatitis (MASH/NASH) Market Revenue Forecast by Country, 2025-2035
6.5.1 China Metabolic Dysfunction-Associated Steatohepatitis (MASH/NASH) Market Size, Opportunities, Growth 2025-2035
6.5.2 India Metabolic Dysfunction-Associated Steatohepatitis (MASH/NASH) Market Size, Opportunities, Growth 2025-2035
6.5.3 Japan Metabolic Dysfunction-Associated Steatohepatitis (MASH/NASH) Market Size, Opportunities, Growth 2025-2035
6.5.4 Australia Metabolic Dysfunction-Associated Steatohepatitis (MASH/NASH) Market Size, Opportunities, Growth 2025-2035
7. Europe Metabolic Dysfunction-Associated Steatohepatitis (MASH/NASH) Market Data, Penetration, and Business Prospects to 2035
7.1 Europe Metabolic Dysfunction-Associated Steatohepatitis (MASH/NASH) Market Key Findings, 2026
7.2 Europe Metabolic Dysfunction-Associated Steatohepatitis (MASH/NASH) Market Size and Percentage Breakdown By Product, 2025-2035
7.3 Europe Metabolic Dysfunction-Associated Steatohepatitis (MASH/NASH) Market Size and Percentage Breakdown By Application, 2025-2035
7.4 Europe Metabolic Dysfunction-Associated Steatohepatitis (MASH/NASH) Market Size and Percentage Breakdown By Sales Channel, 2025-2035
7.5 Europe Metabolic Dysfunction-Associated Steatohepatitis (MASH/NASH) Market Size and Percentage Breakdown by Country, 2025-2035
7.5.1 Germany Metabolic Dysfunction-Associated Steatohepatitis (MASH/NASH) Market Size, Trends, Growth Outlook to 2035
7.5.2 United Kingdom Metabolic Dysfunction-Associated Steatohepatitis (MASH/NASH) Market Size, Trends, Growth Outlook to 2035
7.5.2 France Metabolic Dysfunction-Associated Steatohepatitis (MASH/NASH) Market Size, Trends, Growth Outlook to 2035
7.5.2 Italy Metabolic Dysfunction-Associated Steatohepatitis (MASH/NASH) Market Size, Trends, Growth Outlook to 2035
7.5.2 Spain Metabolic Dysfunction-Associated Steatohepatitis (MASH/NASH) Market Size, Trends, Growth Outlook to 2035
8. North America Metabolic Dysfunction-Associated Steatohepatitis (MASH/NASH) Market Size, Growth Trends, and Future Prospects to 2035
8.1 North America Snapshot, 2026
8.2 North America Metabolic Dysfunction-Associated Steatohepatitis (MASH/NASH) Market Analysis and Outlook By Product, 2025-2035
8.3 North America Metabolic Dysfunction-Associated Steatohepatitis (MASH/NASH) Market Analysis and Outlook By Application, 2025-2035
8.4 North America Metabolic Dysfunction-Associated Steatohepatitis (MASH/NASH) Market Analysis and Outlook By Sales Channel, 2025-2035
8.5 North America Metabolic Dysfunction-Associated Steatohepatitis (MASH/NASH) Market Analysis and Outlook by Country, 2025-2035
8.5.1 United States Metabolic Dysfunction-Associated Steatohepatitis (MASH/NASH) Market Size, Share, Growth Trends and Forecast, 2025-2035
8.5.1 Canada Metabolic Dysfunction-Associated Steatohepatitis (MASH/NASH) Market Size, Share, Growth Trends and Forecast, 2025-2035
8.5.1 Mexico Metabolic Dysfunction-Associated Steatohepatitis (MASH/NASH) Market Size, Share, Growth Trends and Forecast, 2025-2035
9. South and Central America Metabolic Dysfunction-Associated Steatohepatitis (MASH/NASH) Market Drivers, Challenges, and Future Prospects
9.1 Latin America Metabolic Dysfunction-Associated Steatohepatitis (MASH/NASH) Market Data, 2026
9.2 Latin America Metabolic Dysfunction-Associated Steatohepatitis (MASH/NASH) Market Future By Product, 2025-2035
9.3 Latin America Metabolic Dysfunction-Associated Steatohepatitis (MASH/NASH) Market Future By Application, 2025-2035
9.4 Latin America Metabolic Dysfunction-Associated Steatohepatitis (MASH/NASH) Market Future By Sales Channel, 2025-2035
9.5 Latin America Metabolic Dysfunction-Associated Steatohepatitis (MASH/NASH) Market Future by Country, 2025-2035
9.5.1 Brazil Metabolic Dysfunction-Associated Steatohepatitis (MASH/NASH) Market Size, Share and Opportunities to 2035
9.5.2 Argentina Metabolic Dysfunction-Associated Steatohepatitis (MASH/NASH) Market Size, Share and Opportunities to 2035
10. Middle East Africa Metabolic Dysfunction-Associated Steatohepatitis (MASH/NASH) Market Outlook and Growth Prospects
10.1 Middle East Africa Overview, 2026
10.2 Middle East Africa Metabolic Dysfunction-Associated Steatohepatitis (MASH/NASH) Market Statistics By Product, 2025-2035
10.3 Middle East Africa Metabolic Dysfunction-Associated Steatohepatitis (MASH/NASH) Market Statistics By Application, 2025-2035
10.4 Middle East Africa Metabolic Dysfunction-Associated Steatohepatitis (MASH/NASH) Market Statistics By Sales Channel, 2025-2035
10.5 Middle East Africa Metabolic Dysfunction-Associated Steatohepatitis (MASH/NASH) Market Statistics by Country, 2025-2035
10.5.1 Middle East Metabolic Dysfunction-Associated Steatohepatitis (MASH/NASH) Market Value, Trends, Growth Forecasts to 2035
10.5.2 Africa Metabolic Dysfunction-Associated Steatohepatitis (MASH/NASH) Market Value, Trends, Growth Forecasts to 2035
11. Metabolic Dysfunction-Associated Steatohepatitis (MASH/NASH) Market Structure and Competitive Landscape
11.1 Key Companies in Metabolic Dysfunction-Associated Steatohepatitis (MASH/NASH) Industry
11.2 Metabolic Dysfunction-Associated Steatohepatitis (MASH/NASH) Business Overview
11.3 Metabolic Dysfunction-Associated Steatohepatitis (MASH/NASH) Product Portfolio Analysis
11.4 Financial Analysis
11.5 SWOT Analysis
12. Appendix
12.1 Global Metabolic Dysfunction-Associated Steatohepatitis (MASH/NASH) Market Volume (Tons)
12.1 Global Metabolic Dysfunction-Associated Steatohepatitis (MASH/NASH) Trade and Price Analysis
12.2 Metabolic Dysfunction-Associated Steatohepatitis (MASH/NASH) Parent Market and Other Relevant Analysis
12.3 Publisher Expertise
12.2 Metabolic Dysfunction-Associated Steatohepatitis (MASH/NASH) Industry Report Sources and Methodology

Companies Mentioned

  • Madrigal Pharmaceuticals
  • Novo Nordisk
  • Roche
  • Eli Lilly
  • Viking Therapeutics
  • Inventiva
  • Boehringer Ingelheim
  • Gilead Sciences
  • Galectin Therapeutics
  • Arrowhead Pharmaceuticals

Table Information